ClinicalTrials.gg
CompletedNCT01693068Updated Jan 5, 2018Results posted

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

A Phase 2 interventional study of Pimasertib and Dacarbazine in N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma, sponsored by EMD Serono. Completed at 102 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-05.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
194
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 284 studies in Melanoma with a site in Germany — 37 open to participants now, 71 under way, 20 of them phase 3. Melanoma · Germany.

Enrollment
115th of 249
194 · median 162
Started
2012
with 14 others
Phase 2
80 of 284
6 open now
Registered
100th of 284
by date

Among the 284 studies in Melanoma with a site in Germany, this one is the 115th largest by enrollment of the 249 interventional ones that give a count, is one of 15 that started in 2012, is one of 80 in phase 2, and was the 100th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

37 of the 284 studies in Melanoma with a site in Germany are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Melanoma with a site in Germany, or all of them as a file.
02

Study summary

This is a Phase 2, multicenter, randomized, controlled, open-label trial of pimasertib versus dacarbazine aimed to confirm the activity of pimasertib in previously untreated subjects with N-Ras mutated locally advanced or metastatic malignant cutaneous melanoma by comparing the progression-free survival (PFS) of subjects treated with either pimasertib or dacarbazine and by getting a better understanding of the efficacy, safety, pharmacogenomics (PGx) and their relationship with pimasertib exposure.

03

Conditions studied

  • N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma

Browse trials for

Keywords

  • Cutaneous Melanoma
  • Dacarbazine
  • Pimasertib
  • N-Ras
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with measurable, or cytologically confirmed, locally advanced or cutaneous melanoma (stage III c or M1ac) N-Ras mutated. If N-Ras mutational status is unknown at screening, it must be prospectively defined before inclusion. If N-Ras mutational status is already known before screening, it must be retrospectively confirmed after inclusion by the sponsor.
  • Tumor lesions amenable to or available tumor tissue as archival samples.
  • Age greater than or equal to (>=) 18 years.
  • Has read and understood the form and is willing and able to give informed consent. Fully understands requirements of the trial and willing to comply with all trial visits and assessments.
  • Women of must have a negative blood pregnancy test at the screening visit. For the purposes of this trial, women of childbearing potential are defined as: "All female subjects after puberty unless they are for at least two years, or are surgically sterile".
  • Female subjects of childbearing potential and male subjects with female partners of childbearing potential must be willing to avoid pregnancy by using an adequate method of for 2 weeks prior to, during and four weeks after the last dose of trial medication. Effective contraception is defined as the method of contraception with a failure rate of less than 1% per year. Adequate contraception is defined as follows: two barrier methods or one barrier method with a spermicidal or intrauterine device or oral contraception for female partners of male subjects.

Exclusion criteria

Exclusion Criteria:

  • Has previous systemic treatment for locally advanced or cutaneous melanoma (excluding treatment).
  • Has non-, disease not evaluable by (RECIST) v. 1.1
  • Has an performance status (ECOG PS) >1.
  • Has bone marrow impairment as evidenced by \<10.0 g/dL, \<1.5 * 10\^9/L, \<100 * 10\^9/L.
  • Has renal impairment as evidenced by calculated \<60 mL/min (according to the Cockcroft-Gault formula).
  • Has liver function abnormality as defined by total >1.5 * (ULN), or (AST)/alanine aminotransferase (ALT) >2.5 * ULN, for subjects with liver involvement AST/ALT >5 * ULN.
  • Has significant cardiac conduction abnormalities, including prolongation of >480 milliseconds and/or pacemaker or impaired cardiovascular function.
  • Has hypertension uncontrolled by medication
  • Has retinal degenerative disease (hereditary retinal degeneration or age-related macular degeneration), history of uveitis, or history of retinal vein occlusion (RVO) or any eye condition that would be considered a risk factor for RVO (e.g., uncontrolled glaucoma or ocular hypertension).
  • Has known active central nervous system (CNS) metastases unless previously radiotherapy treated, stable by CT scan for at least 3 months without evidence of cerebral edema and no requirements for or anticonvulsants.
  • History of difficulty swallowing, malabsorption or other chronic gastro-intestinal disease, or conditions that may hamper compliance and/or absorption of the tested product.
  • Known (HIV) positivity, active , or active .
  • Has undergone surgical intervention within 28 days from Day 1 of trial drug treatment.
  • Has received extensive prior radiotherapy on more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation within 5 years from Day 1 of trial drug treatment.
  • Has history of any other significant medical disease such as major gastric or small bowel surgery, recent drainage of significant volumes of ascites or pleural effusion or has a psychiatric condition that might impair the subject well-being or preclude full participation in the trial.
  • Has known to dacarbazine.
  • Is a pregnant or nursing female.
  • Participated in another clinical trial within the past 28 days.
  • Has creatine phosphokinase (CPK) level at baseline National Cancer Institute (NCI CTCAE) Grade >=2 (i.e > 2.5 * ULN), and/or has a previous history of myositis or rhabdomyolysis.
  • Is suitable for treatment with an approved B-Raf inhibitor (exclusion criteria implemented in German amendment only).
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
194 participants (actual)

Study arms

  • Experimental
    Pimasertib

    Drug: Pimasertib

  • Active comparator
    Dacarbazine

    Drug: Dacarbazine

Interventions

  • Subjects will receive pimasertib orally as monotherapy at a dose of 60 milligram (mg) twice daily continuously. Treatment will consist of repeated 21-day cycles which will continue until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first.

    Also known as: MSC1936369B, AS703026

  • Subjects will receive dacarbazine intravenously at dose of 1000 milligram per square meter (mg/m\^2) of body surface area every 3 weeks on Day 1 of each 21-days cycle until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first. Eligible subjects with documented tumor progression on dacarbazine will offer to switch to pimasertib treatment.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the duration (in weeks) from randomization until the first progressive disease (PD) observation as assessed by the Investigator according to Response Evaluation Criteria for Solid Tumors (RECIST) version 1.1, or death due to any cause when death occurred within 12 weeks after the last tumor assessment (otherwise censored), whichever occurred first. PD was defined as at least a 20% increase in the sum of diameters of the target lesions, taking as reference the smallest sum since the treatment started (including baseline), or appearance of one or more new lesions, and/or unequivocal progression of existing non-target lesions.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to cut-off date (04-Jul-2015)

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR was defined as the percentage of subjects with complete response (CR) or partial response (PR) according to RECIST version 1.1 criteria. CR: defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR: defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters along with absence of new lesions and disease progression in non-target lesions.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to cut-off date (04-Jul-2015)

  2. Disease Control Rate (DCR)

    DCR was defined as the percentage of subjects with CR, PR, or stable disease (SD) for greater than (\>) 3 months assessed by investigator according to RECIST version 1.1. CR: defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than \<10 mm. PR: defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters along with absence of new lesions and disease progression in non-target lesions. SD: defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to cut-off date (04-Jul-2015)

  3. Percentage of Subjects With Progression-free Survival (PFS) at 6 Months

    PFS was defined as the duration (in weeks) from randomization until the first progressive disease (PD) observation as assessed by the Investigator according to Response Evaluation Criteria for Solid Tumors (RECIST) version 1.1, or death due to any cause when death occurred within 12 weeks after the last tumor assessment, whichever occurred first. PD was defined as at least a 20% increase in the sum of diameters of the target lesions, taking as reference the smallest sum since the treatment started (including baseline), or appearance of one or more new lesions, and/or unequivocal progression of existing non-target lesions. Percentage of Subjects with PFS at 6 Months were reported.

    Time frame: 6 months

  4. Overall Survival (OS)

    OS was defined as the time (in months) from randomization to death due to any cause. Subjects without a death date were to be censored at the minimum of last known date alive, defined as the latest date available on the electronic case report form, and cut-off date.

    Time frame: From date of randomization until date of death from any cause, assessed up to cut-off date (04-Jul-2015)

  5. Percentage of Subjects With Overall Survival (OS) at 12 Months

    OS was defined as the time (in months) from randomization to death due to any cause. Subjects without a death date were to be censored at the minimum of last known date alive, defined as the latest date available on the electronic case report form, and cut-off date. Percentage of Subjects with OS at 12 months were reported.

    Time frame: 12 months

  6. Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT)

    QoL assessed using Function Assessment Cancer Therapy-melanoma (FACT-M) assessment tool. This includes 27-item FACT-General (FACT-G) questionnaire which consists of 24 questions;7 relating to physical well-being (PWB),7 relating to social/family well-being (SWB),6 relating to emotional well-being (EWB) and 7 relating to functional well-being (FWB). Also, it includes melanoma-specific subscale consists of 16 questions for Melanoma Subscale (MS) and 8 questions for Melanoma Surgery Scale (MSS).Each of these questions could have a response of Not at all, a little bit, somewhat, quite a bit and very much. The responses were given a value between 0 and 4 with 4 being best response. The FACT-M Total Score (FACT-M TS) ranges from 0 to 172 and is derived as follows: FACT-M TS= PWB Score + SWB Score + EWB Score + FWB Score + MS Score. Higher scores represent a better quality of life.

    Time frame: Baseline, Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 30, 31, 32, 33, 35, 36, 37 and EOT (up to cut-off date [04-Jul-2015])

  7. Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT)

    QoL assessed using FACT-M assessment tool. This includes 27-item FACT-G questionnaire which consists of 24 questions; 7 relating to PWB, 7 relating to SWB, 6 relating to EWB and 7 relating to FWB. Also, it includes melanoma-specific subscale consists of 16 questions for MS and 8 questions for the MSS. Each of these questions could have a response of Not at all, a little bit, somewhat, quite a bit and very much. The responses were given a value between 0 and 4 with 4 being best response. The FACT-M Trial Outcome Index (FACT-M TOI) ranges from 0 to a high of 120 and is derived as: FACT-M TOI = PWB Score + FWB Score +MS Score. Higher scores represent a better quality of life.

    Time frame: Baseline, Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 30, 31, 32, 33, 35, 36, 37 and EOT (up to cut-off date [04-Jul-2015])

  8. Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation or TEAEs Leading to Death

    AE was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug and up to 33 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. TEAEs include both Serious TEAEs and non-serious TEAEs. TEAEs were to be reported separately for dacarbazine, pimasertib and pimasertib (crossover) reporting arms.

    Time frame: Baseline up to cut-off date (04-Jul-2015)

  9. Number of Subjects With Adverse Events (AEs) of Special Interest

    Adverse events of special interest included ocular retinal vein occlusion, serious retinal detachment or similar retinal abnormality characterized by accumulation of serous fluid in the retina, creatine phosphokinase (CPK) elevation and isoenzyme TEAE of Special Interest (Grade \>=2) and acute renal failure (Grade \>=2). Subjects were presented under 3 reporting groups: Dacarbazine group: for subjects who received at least 1 dose of dacarbazine; Pimasertib group: for subjects who received at least 1 dose of pimasertib; Pimasertib (Crossover) group: for subjects who were initially randomized and received dacarbazine, but crossed over to pimasertib treatment on progression of their disease.

    Time frame: Baseline up to cut-off date (04-Jul-2015)

  10. Number of Subjects With Clinically Significant Change From Baseline in Laboratory Parameter, Vital Signs, Electrocardiogram (ECG) and Ophthalmologic Findings

    Subjects were presented under 3 reporting groups: Dacarbazine group: for subjects who received at least 1 dose of dacarbazine; Pimasertib group: for subjects who received at least 1 dose of pimasertib; Pimasertib (Crossover) group: for subjects who were initially randomized and received dacarbazine, but crossed over to pimasertib treatment on progression of their disease.

    Time frame: Baseline up to cut-off date (04-Jul-2015)

07

Results

Posted Jan 5, 2018

Participant flow

First/last subject (informed consent): 05 December 2012/04 June 2014. Cut-off date: 04 July 2015. Last subject last visit: 24 October 2016.

Randomization Period
Participant flow — Randomization Period
MilestoneDacarbazinePimasertibPimasertib (Crossover)
Started641300
Treated611300
Completed621250
Not completed250
Withdrew: On-study250
Cross-over (Dacarbazine To Pimasertib)
Participant flow — Cross-over (Dacarbazine To Pimasertib)
MilestoneDacarbazinePimasertibPimasertib (Crossover)
Started0041
Treated0041
Completed0040
Not completed001
Withdrew: On-study001

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS was defined as the duration (in weeks) from randomization until the first progressive disease (PD) observation as assessed by the Investigator according to Response Evaluation Criteria for Solid Tumors (RECIST) version 1.1, or death due to any cause when death occurred within 12 weeks after the last tumor assessment (otherwise censored), whichever occurred first. PD was defined as at least a 20% increase in the sum of diameters of the target lesions, taking as reference the smallest sum since the treatment started (including baseline), or appearance of one or more new lesions, and/or unequivocal progression of existing non-target lesions.

Time frame:
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to cut-off date (04-Jul-2015)
Reported as:
Median · weeks
Progression Free Survival (PFS)
weeksDacarbazinePimasertib
Progression Free Survival (PFS)6.86 (6.00 to 12.14)13.00 (12.29 to 17.71)
Statistical analysis
  • Dacarbazine vs Pimasertib · Stratified Log Rank Test · p = 0.0022 · Hazard ratio (hr): 0.59 · 95% CI 0.42 to 0.83The Hazard Ratio is obtained from the Cox Proportional Hazards model based on dacarbazine and pimasertib only stratified by baseline ECOG Performance Status.
SecondaryObjective Response Rate (ORR)

ORR was defined as the percentage of subjects with complete response (CR) or partial response (PR) according to RECIST version 1.1 criteria. CR: defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR: defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters along with absence of new lesions and disease progression in non-target lesions.

Time frame:
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to cut-off date (04-Jul-2015)
Reported as:
Number · percentage of subjects
Objective Response Rate (ORR)
percentage of subjectsDacarbazinePimasertib
Objective Response Rate (ORR)14.1 (6.6 to 25.0)26.9 (19.5 to 35.4)
SecondaryDisease Control Rate (DCR)

DCR was defined as the percentage of subjects with CR, PR, or stable disease (SD) for greater than (\>) 3 months assessed by investigator according to RECIST version 1.1. CR: defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than \<10 mm. PR: defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters along with absence of new lesions and disease progression in non-target lesions. SD: defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to cut-off date (04-Jul-2015)
Reported as:
Number · percentage of subjects
Disease Control Rate (DCR)
percentage of subjectsDacarbazinePimasertib
Disease Control Rate (DCR)15.6 (7.8 to 26.9)33.1 (25.1 to 41.9)
SecondaryPercentage of Subjects With Progression-free Survival (PFS) at 6 Months

PFS was defined as the duration (in weeks) from randomization until the first progressive disease (PD) observation as assessed by the Investigator according to Response Evaluation Criteria for Solid Tumors (RECIST) version 1.1, or death due to any cause when death occurred within 12 weeks after the last tumor assessment, whichever occurred first. PD was defined as at least a 20% increase in the sum of diameters of the target lesions, taking as reference the smallest sum since the treatment started (including baseline), or appearance of one or more new lesions, and/or unequivocal progression of existing non-target lesions. Percentage of Subjects with PFS at 6 Months were reported.

Time frame:
6 months
Reported as:
Number · percentage of subjects
Percentage of Subjects With Progression-free Survival (PFS) at 6 Months
percentage of subjectsDacarbazinePimasertib
Percentage of Subjects With Progression-free Survival (PFS) at 6 Months9.4 (3.6 to 18.6)17.3 (10.2 to 26.0)
SecondaryOverall Survival (OS)

OS was defined as the time (in months) from randomization to death due to any cause. Subjects without a death date were to be censored at the minimum of last known date alive, defined as the latest date available on the electronic case report form, and cut-off date.

Time frame:
From date of randomization until date of death from any cause, assessed up to cut-off date (04-Jul-2015)
Reported as:
Median · months
Overall Survival (OS)
monthsDacarbazinePimasertib
Overall Survival (OS)10.61 (7.26 to 16.49)8.87 (7.46 to 15.51)
SecondaryPercentage of Subjects With Overall Survival (OS) at 12 Months

OS was defined as the time (in months) from randomization to death due to any cause. Subjects without a death date were to be censored at the minimum of last known date alive, defined as the latest date available on the electronic case report form, and cut-off date. Percentage of Subjects with OS at 12 months were reported.

Time frame:
12 months
Reported as:
Number · percentage of subjects
Percentage of Subjects With Overall Survival (OS) at 12 Months
percentage of subjectsDacarbazinePimasertib
Percentage of Subjects With Overall Survival (OS) at 12 Months44.5 (31.6 to 56.6)43.3 (34.5 to 51.8)
SecondaryChange From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT)

QoL assessed using Function Assessment Cancer Therapy-melanoma (FACT-M) assessment tool. This includes 27-item FACT-General (FACT-G) questionnaire which consists of 24 questions;7 relating to physical well-being (PWB),7 relating to social/family well-being (SWB),6 relating to emotional well-being (EWB) and 7 relating to functional well-being (FWB). Also, it includes melanoma-specific subscale consists of 16 questions for Melanoma Subscale (MS) and 8 questions for Melanoma Surgery Scale (MSS).Each of these questions could have a response of Not at all, a little bit, somewhat, quite a bit and very much. The responses were given a value between 0 and 4 with 4 being best response. The FACT-M Total Score (FACT-M TS) ranges from 0 to 172 and is derived as follows: FACT-M TS= PWB Score + SWB Score + EWB Score + FWB Score + MS Score. Higher scores represent a better quality of life.

Time frame:
Baseline, Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 30, 31, 32, 33, 35, 36, 37 and EOT (up to cut-off date [04-Jul-2015])
Reported as:
Mean · units on a scale
Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Total Score (FACT-M TS) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT)
units on a scaleDacarbazinePimasertib
Baseline126.20 ± 23.828132.24 ± 22.179
Change at Day 1 Cycle 2-3.05 ± 14.815-3.06 ± 18.492
Change at Day 1 Cycle 30.60 ± 19.965-6.77 ± 21.716
Change at Day 1 Cycle 44.11 ± 14.746-6.54 ± 19.919
Change at Day 1 Cycle 50.62 ± 11.810-2.81 ± 17.202
Change at Day 1 Cycle 6-3.71 ± 15.674-8.45 ± 20.939
Change at Day 1 Cycle 7-1.10 ± 13.318-8.84 ± 19.128
Change at Day 1 Cycle 81.28 ± 12.928-14.67 ± 18.508
Change at Day 1 Cycle 92.21 ± 16.224-13.67 ± 21.388
Change at Day 1 Cycle 104.40 ± 14.818-13.26 ± 20.716
Change at Day 1 Cycle 111.02 ± 19.161-14.10 ± 21.157
Change at Day 1 Cycle 121.56 ± 19.932-10.52 ± 18.895
Change at Day 1 Cycle 135.51 ± 20.191-13.38 ± 23.690
Change at Day 1 Cycle 1411.50 ± 21.920-18.24 ± 22.998
Change at Day 1 Cycle 159.60 ± 15.345-11.33 ± 19.787
Change at Day 1 Cycle 1610.56 ± 14.935-11.18 ± 23.680
Change at Day 1 Cycle 173.00 ± 5.657-9.18 ± 24.166
Change at Day 1 Cycle 1827.00 ± NA-3.92 ± 9.640
Change at Day 1 Cycle 1916.50 ± 14.849-1.15 ± 8.147
Change at Day 1 Cycle 2016.00 ± 15.5561.17 ± 5.947
Change at Day 1 Cycle 2117.00 ± 14.1424.17 ± 8.918
Change at Day 1 Cycle 2218.00 ± 12.7281.32 ± 11.163
Change at Day 1 Cycle 2327.00 ± NA-13.69 ± 15.354
Change at Day 1 Cycle 2413.50 ± 19.092-3.83 ± NA
Change at Day 1 Cycle 2514.50 ± 17.678-3.83 ± NA
Change at Day 1 Cycle 2627.00 ± NA-2.83 ± NA
Change at Day 1 Cycle 2727.00 ± NA—
Change at Day 1 Cycle 2827.00 ± NA-0.83 ± NA
Change at Day 1 Cycle 30—-1.83 ± NA
Change at Day 1 Cycle 31—-7.83 ± NA
Change at Day 1 Cycle 32—-7.83 ± NA
Change at Day 1 Cycle 33—-8.83 ± NA
Change at Day 1 Cycle 35—-1.83 ± NA
Change at Day 1 Cycle 36—-3.83 ± NA
Change at Day 1 Cycle 37—-4.83 ± NA
Change at EOT-7.91 ± 23.119-9.98 ± 20.560
SecondaryChange From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT)

QoL assessed using FACT-M assessment tool. This includes 27-item FACT-G questionnaire which consists of 24 questions; 7 relating to PWB, 7 relating to SWB, 6 relating to EWB and 7 relating to FWB. Also, it includes melanoma-specific subscale consists of 16 questions for MS and 8 questions for the MSS. Each of these questions could have a response of Not at all, a little bit, somewhat, quite a bit and very much. The responses were given a value between 0 and 4 with 4 being best response. The FACT-M Trial Outcome Index (FACT-M TOI) ranges from 0 to a high of 120 and is derived as: FACT-M TOI = PWB Score + FWB Score +MS Score. Higher scores represent a better quality of life.

Time frame:
Baseline, Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 30, 31, 32, 33, 35, 36, 37 and EOT (up to cut-off date [04-Jul-2015])
Reported as:
Mean · units on a scale
Change From Baseline in Subject-reported Quality of Life Assessed by Functional Assessment Cancer Therapy - Melanoma Trial Outcome Index (FACT-M TOI) at Day 1 of Pre-Specified Cycles and End of Treatment (EOT)
units on a scaleDacarbazinePimasertib
Baseline90.35 ± 19.34894.07 ± 17.534
Change at Day 1 Cycle 2-3.33 ± 12.015-4.40 ± 14.286
Change at Day 1 Cycle 3-0.69 ± 15.974-7.99 ± 17.089
Change at Day 1 Cycle 41.54 ± 10.304-7.97 ± 16.741
Change at Day 1 Cycle 5-0.86 ± 5.405-4.37 ± 14.084
Change at Day 1 Cycle 6-3.29 ± 7.752-9.15 ± 18.813
Change at Day 1 Cycle 7-2.07 ± 6.859-8.99 ± 14.783
Change at Day 1 Cycle 80.83 ± 5.161-15.09 ± 14.458
Change at Day 1 Cycle 9-1.93 ± 6.300-13.79 ± 17.198
Change at Day 1 Cycle 10-1.10 ± 5.654-12.37 ± 17.058
Change at Day 1 Cycle 11-2.90 ± 7.722-13.95 ± 17.006
Change at Day 1 Cycle 12-2.40 ± 7.408-11.95 ± 17.311
Change at Day 1 Cycle 130.80 ± 7.697-13.57 ± 21.699
Change at Day 1 Cycle 140.00 ± 4.243-18.55 ± 19.880
Change at Day 1 Cycle 151.60 ± 4.084-13.59 ± 15.747
Change at Day 1 Cycle 160.61 ± 3.994-13.15 ± 19.130
Change at Day 1 Cycle 172.50 ± 0.707-10.66 ± 20.007
Change at Day 1 Cycle 183.00 ± NA-5.72 ± 4.614
Change at Day 1 Cycle 192.50 ± 0.707-4.94 ± 5.238
Change at Day 1 Cycle 204.00 ± 1.414-2.33 ± 1.155
Change at Day 1 Cycle 213.50 ± 0.7070.00 ± 2.000
Change at Day 1 Cycle 224.00 ± 1.414-1.40 ± 3.831
Change at Day 1 Cycle 233.00 ± NA-13.36 ± 16.061
Change at Day 1 Cycle 242.50 ± 0.707-2.00 ± NA
Change at Day 1 Cycle 253.50 ± 0.707-1.00 ± NA
Change at Day 1 Cycle 263.00 ± NA0.00 ± NA
Change at Day 1 Cycle 273.00 ± NA—
Change at Day 1 Cycle 283.00 ± NA1.00 ± NA
Change at Day 1 Cycle 30—1.00 ± NA
Change at Day 1 Cycle 31—-3.00 ± NA
Change at Day 1 Cycle 32—-4.00 ± NA
Change at Day 1 Cycle 33—-3.00 ± NA
Change at Day 1 Cycle 35—0.00 ± NA
Change at Day 1 Cycle 36—0.00 ± NA
Change at Day 1 Cycle 37—-3.00 ± NA
Change at EOT-8.18 ± 16.410-10.42 ± 16.256
SecondaryNumber of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation or TEAEs Leading to Death

AE was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug and up to 33 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. TEAEs include both Serious TEAEs and non-serious TEAEs. TEAEs were to be reported separately for dacarbazine, pimasertib and pimasertib (crossover) reporting arms.

Time frame:
Baseline up to cut-off date (04-Jul-2015)
Reported as:
Number · subjects
Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation or TEAEs Leading to Death
subjectsDacarbazinePimasertibPimasertib (Crossover)
TEAEs6013041
Serious TEAEs127426
TEAEs Leading to Discontinuation36116
TEAEs Leading To Death466
SecondaryNumber of Subjects With Adverse Events (AEs) of Special Interest

Adverse events of special interest included ocular retinal vein occlusion, serious retinal detachment or similar retinal abnormality characterized by accumulation of serous fluid in the retina, creatine phosphokinase (CPK) elevation and isoenzyme TEAE of Special Interest (Grade \>=2) and acute renal failure (Grade \>=2). Subjects were presented under 3 reporting groups: Dacarbazine group: for subjects who received at least 1 dose of dacarbazine; Pimasertib group: for subjects who received at least 1 dose of pimasertib; Pimasertib (Crossover) group: for subjects who were initially randomized and received dacarbazine, but crossed over to pimasertib treatment on progression of their disease.

Time frame:
Baseline up to cut-off date (04-Jul-2015)
Reported as:
Number · subjects
Number of Subjects With Adverse Events (AEs) of Special Interest
subjectsDacarbazinePimasertibPimasertib (Crossover)
Retinal vein occlusion052
Serious retinal detachment07621
CPK/Isoenzyme TEAE of Special Interest (>=Grade 2)07424
Acute renal failure (Grade >= 2)192
SecondaryNumber of Subjects With Clinically Significant Change From Baseline in Laboratory Parameter, Vital Signs, Electrocardiogram (ECG) and Ophthalmologic Findings

Subjects were presented under 3 reporting groups: Dacarbazine group: for subjects who received at least 1 dose of dacarbazine; Pimasertib group: for subjects who received at least 1 dose of pimasertib; Pimasertib (Crossover) group: for subjects who were initially randomized and received dacarbazine, but crossed over to pimasertib treatment on progression of their disease.

Time frame:
Baseline up to cut-off date (04-Jul-2015)
Reported as:
Number · subjects
Number of Subjects With Clinically Significant Change From Baseline in Laboratory Parameter, Vital Signs, Electrocardiogram (ECG) and Ophthalmologic Findings
subjectsDacarbazinePimasertibPimasertib (Crossover)
Laboratory Parameter000
Vital Signs000
ECG000
Ophthalmologic Findings000

Adverse events

Collected over Baseline up to cut-off date (04-Jul-2015). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dacarbazine—12/61 (19.7%)59/61 (96.7%)
Pimasertib—74/130 (56.9%)130/130 (100%)
Pimasertib (Crossover)—26/41 (63.4%)41/41 (100%)
Most frequent serious events
Showing 10 of 105
Most frequent serious events
EventDacarbazinePimasertibPimasertib (Crossover)
Blood creatine phosphokinase increasedInvestigations0/6126/1308/41
General physical health deteriorationGeneral disorders1/612/1304/41
ErysipelasInfections and infestations0/617/1301/41
ThrombocytopeniaBlood and lymphatic system disorders3/610/1300/41
AnaemiaBlood and lymphatic system disorders1/610/1302/41
Small intestinal obstructionGastrointestinal disorders0/610/1302/41
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/613/1302/41
DiarrhoeaGastrointestinal disorders1/616/1301/41
Ejection fraction decreasedInvestigations0/615/1301/41
DyspnoeaRespiratory, thoracic and mediastinal disorders0/615/1300/41
Most frequent other events
Showing 10 of 583
Most frequent other events
EventDacarbazinePimasertibPimasertib (Crossover)
DiarrhoeaGastrointestinal disorders10/61106/13031/41
Blood creatine phosphokinase increasedInvestigations3/6186/13028/41
Oedema peripheralGeneral disorders6/6159/13018/41
RashSkin and subcutaneous tissue disorders5/6146/13018/41
Retinal detachmentEye disorders0/6156/13015/41
NauseaGastrointestinal disorders25/6147/13017/41
VomitingGastrointestinal disorders14/6130/13016/41
FatigueGeneral disorders23/6139/13011/41
Dermatitis acneiformSkin and subcutaneous tissue disorders0/6147/1309/41
ConstipationGastrointestinal disorders21/6124/1307/41

Baseline characteristics

Intent-to-treat (ITT) analysis set included all subjects who were randomized to trial treatment.

Age, Categorical
Age, Categorical(Participants)DacarbazinePimasertibTotal
<=18 years000
Between 18 and 65 years3665101
>=65 years286593
Sex: Female, Male
Sex: Female, Male(Participants)DacarbazinePimasertibTotal
Female286290
Male3668104
08

Study locations

102 sites
  • Research Site
    Birmingham, Alabama, United States
  • Research Site
    Tucson, Arizona, United States
  • Research Site
    San Francisco, California, United States
  • Research Site
    Miami Beach, Florida, United States
  • Research Site
    Orlando, Florida, United States
  • Research Site
    Maywood, Illinois, United States
  • Research Site
    Indianapolis, Indiana, United States
  • Research Site
    Boston, Massachusetts, United States
  • Please contact the US Medical Information in
    Rockland, Massachusetts, United States
  • Research Site
    Saint Louis, Missouri, United States
  • Research Site
    Morristown, New Jersey, United States
  • Research Site
    New York, New York, United States
  • Research Site
    Columbus, Ohio, United States
  • Research Site
    Dallas, Texas, United States
  • Research Site
    Madison, Wisconsin, United States
  • Research Site
    Adelaide, SA, Australia
  • Research Site
    Albury/Wodonga, Australia
  • Research Site
    Auchenflower, Australia
  • Research Site
    Box Hill, Australia
  • Research Site
    Greenslopes, Australia
  • Research Site
    Herston, Australia
  • Research Site
    Malvern, Australia
  • Research Site
    North Sydney, Australia
  • Research Site
    Prahran, Australia
  • Research Site
    Wendouree, Australia
  • Research Site
    Woodville South, Australia
  • Research site
    Woolloongabba, Australia
  • Research Site
    Brussel, Belgium
  • Research Site
    Bruxelles, Belgium
  • Research Site
    Edegem, Belgium
  • Research Site
    Bordeaux, France
  • Research Site
    Brest, France
  • Research Site
    Dijon, France
  • Research Site
    Lille, France
  • Research Site
    Lyon, France
  • Research Site
    Marseille, France
  • Research Site
    Montpellier, France
  • Research Site
    Nantes, France
  • Research Site
    Paris, France
  • Research Site
    Pierre Benite, France
  • Research Site
    Rennes, France
  • Research Site
    Toulouse, France
  • Research Site
    Villejuif, France
  • Research Site
    Augsburg, Germany
  • Research Site
    Berlin, Germany
  • Research Site
    Bonn, Germany
  • Research Site
    Buxtehude, Germany
  • Research site
    Düsseldorf, Germany
  • Research Site
    Erlangen, Germany
  • Research Site
    Essen, Germany
  • Research Site
    Frankfurt am Main, Germany
  • Research Site
    Hamburg, Germany
  • Research Site
    Hannover, Germany
  • Research Site
    Kiel, Germany
  • Research Site
    Köln, Germany
  • Research Site
    Leipzig, Germany
  • Research Site
    Magdeburg, Germany
  • Research Site
    Mainz, Germany
  • Research site
    München, Germany
  • Research Site
    Münster, Germany
  • Research Site
    Plauen, Germany
  • Research Site
    Tübingen, Germany
  • Research Site
    Würzburg, Germany
  • Research Site
    Jerusalem, Israel
  • Research Site
    Ramat-Gan, Israel
  • Research Site
    Tel-Aviv, Israel
  • Research Site
    Bari, Italy
  • Research Site
    Genova, Italy
  • Research Site
    Meldola - FC, Italy
  • Research Site
    Milano, Italy
  • Research Site
    Napoli, Italy
  • Research Site
    Padova, Italy
  • Research Site
    Roma, Italy
  • Research Site
    Siena, Italy
  • Research Site
    Groningen, Netherlands
  • Research Site
    Rotterdam, Netherlands
  • Research Site
    Utrecht, Netherlands
  • Research Site
    Christchurch, New Zealand
  • Research Site
    Hamilton, New Zealand
  • Research Site
    Palmerston North, New Zealand
  • Research Site
    Tauranga, New Zealand
  • Research Site
    Durban, South Africa
  • Research Site
    Johannesburg, South Africa
  • Research Site
    Pietermaritzburg, South Africa
  • Research Site
    Pretoria, South Africa
  • Research Site
    Badalona, Spain
  • Research Site
    Barcelona, Spain
  • Research Site
    l'Hospitalet de Llobregat, Spain
  • Research Site
    Madrid, Spain
  • Research Site
    Majadahonda, Spain
  • Research Site
    Málaga, Spain
  • Research Site
    Pamplona, Spain
  • Research Site
    Sevilla, Spain
  • Research Site
    Göteborg, Sweden
  • Research Site
    Stockholm, Sweden
  • Research Site
    Basel, Switzerland
  • Research Site
    Zürich, Switzerland
  • Research Site
    Cambridge, United Kingdom
  • Research Site
    London, United Kingdom
  • Research Site
    Manchester, United Kingdom

Showing the first 100 of 102 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Lebbe C, Dutriaux C, Lesimple T, Kruit W, Kerger J, Thomas L, Guillot B, Braud F, Garbe C, Grob JJ, Loquai C, Ferraresi V, Robert C, Vasey P, Conry R, Isaacs R, Espinosa E, Schueler A, Massimini G, Dreno B. Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. Cancers (Basel). 2020 Jun 29;12(7):1727. doi: 10.3390/cancers12071727. PubMed 32610581 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2012 to primary completion in Jul 2015, 30 months.

Results were first posted in Jan 2018, 2 years 6 months after primary completion.

Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 30 months is below that.

Counting every sponsor, half of 384 studies reached it within 53 months; a quarter within 32 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2012
First posted
Sep 26, 2012
StartActual
Dec 5, 2012
Primary completionActual
Jul 4, 2015
CompletionActual
Oct 24, 2016
Results first posted
Jan 5, 2018
Last update
Jan 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01693068
Lead sponsor
EMD Serono
Responsible party
Sponsor
First posted
Sep 26, 2012
Start date
Dec 5, 2012
Primary completion
Jul 4, 2015
Completion
Oct 24, 2016
Results posted
Jan 5, 2018
Last update
Jan 5, 2018

Study contacts

Study Director
study director · EMD Serono Inc., a business of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pimasertib

Start the discussion